A new AstraZeneca inhaler for chronic lung disease proved worse than a rival GlaxoSmithKline product in a clinical trial.
A toxin inadvertently produced in the manufacture of a widely prescribed medicine but not spotted for years raises questions about regulators’ ability to detect risks in a sprawling global drug supply chain increasingly reliant on factories in China.
Heart drugs containing an active ingredient from a second Chinese company are being recalled from the European market after detection of a toxic impurity that may cause cancer.
U.S. Health and Human Services Secretary Alex Azar said it was within his agency’s power to eliminate rebates on prescription drug purchases, a key element of the Trump administration’s plan to lower prescription medicine costs.
Japan’s Eisai Co. Ltd. will price the company’s cancer drug Lenvima at about $16,000 for a month’s supply before discounts, after the U.S. Food and Drug Administration approved the product’s use in patients with a common form of liver cancer.
The Trump administration said it was proposing that U.S. pharmaceutical companies cut production of the six most abused opioids by 10 percent next year.
Biogen’s muscle disease treatment Spinraza has been deemed too expensive for use on Britain’s state-run health service, even after a price discount offered by the U.S. drugmaker.
Amicus Therapeutics set an average price of $315,000 per year for the company’s newly approved Fabry disease treatment.
A unit of India’s Hetero Drugs is recalling some batches of the blood pressure and heart medicine valsartan in the United States amid a wider probe into cancer risks associated with the drug.
GW Pharmaceuticals revealed a $32,500 price for the company’s cannabis-based epilepsy drug Epidiolex.